The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2006Molecular Regulators of Dopamine Synthesis
The death of certain brain cells known as nigrostriatal neurons, which produce the neurochemical known as dopamine, ultimately causes movement dysfunction and reduced quality of life for individuals...
-
Community Fast Track, 2006Establishing a role of Nurr1 in adult DA neurons by conditional gene ablation in the adult substantia nigra
We will investigate the function of the protein Nurr1 in the adult mouse brain. Nurr1 belongs to the family of steroid hormone receptors but lacks an identified ligand. We have previously shown that...
-
Community Fast Track, 2006Engrailed as a Potential Therapeutic Target in Parkinson's Disease
Parkinson’s disease is associated with the preferential loss of a population of dopaminergic neurons in the substantia nigra, a specific structure of the midbrain. It was shown very recently that...
-
Community Fast Track, 2006Study of the Role of Phosphorylation at Ser 129 in Alpha-synuclein Induced Dopaminergic Neurodegeneration in a Rodent Model of Parkinson's Disease
The involvement of alpha-synuclein in Parkinson's disease neurodegeneration is now widely accepted. However, factors and events contributing to the alpha-synuclein toxicity are still being...
-
Community Fast Track, 2006CDNF a novel conserved neurotrophic factor that protects midbrain dopaminergic neurons in vivo
Neuroprotective or neurorestorative therapies for Parkinson's disease are still evolving. We have identified a novel conserved dopamine neurotrophic factor (CDNF) protein which might be beneficial for...
-
Community Fast Track, 2006Specific Intracellular Targeting of Oligomeric Alpha-synuclein as a Potential Therapeutic for Parkinson's Disease
The protein alpha-synuclein is a major constituent of the Lewy Body aggregates that are a hallmark feature of Parkinson's disease. Several genetic studies have also correlated aggregation of alpha...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.